BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection

2026-02-09 01:10:13 ET

Initiating BridgeBio with a neutral rating

I initiate coverage of Bridge Bio ( BBIO ) with a neutral rating, which reflects the balance between tangible de-risking following the US approval/early commercialization of acoramidis (Attruby) in the transthyretin amyloid cardiomyopathy (ATTR-CM), and persistent uncertainty around the long-term competitive positioning, pricing durability, and capital intensity of the company....

Read the full article on Seeking Alpha

For further details see: